Clinical trials: Moderate and Severe Active Rheumatoid Arthritis
- Condition Moderate and Severe Active Rheumatoid Arthritis
- Funder type Industry (pharma, biotech, devices)
Rheumatoid Arthritis
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
This multi-center, randomized, parallel-group, active-controlled, open-label study will evaluate the safety and efficacy of a shortened RoActemra/Actemra (tocilizumab) infusion time compared to the normal infusion time.
- Trial name
- NCT01468077
- Testing
- Tocilizumab
- Where
- 8 sites in Denmark, Iceland
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic…
- Trial name
- NCT06859294
- Testing
- LY3541860
- Where
- 20 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis(RA)
A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX
To demonstrate that SM03 added to methotrexate (MTX) reduce signs and symptoms of rheumatoid arthritis (RA) in Chinese RA participants with an inadequate response to MTX.
- Trial name
- NCT04312815
- Testing
- SM03, MTX
- Where
- China
- Volunteers
- 510 people
- Sponsor
- SinoMab BioScience Ltd
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
This open-label study will evaluate the safety, tolerability and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis (RA) on background non-biologic DMARDs who have an…
- Trial name
- NCT01245439
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 17 sites in Turkey (Türkiye)
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
Primary Objective: -To demonstrate that sarilumab added to methotrexate (MTX) reduce signs and symptoms of rheumatoid arthritis (RA) in Japanese RA participants with an inadequate response to MTX.
- Trial name
- NCT02293902
- Testing
- Sarilumab SAR153191 (REGN88), Methotrexate, Folic acid
- Where
- 96 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in…
- Trial name
- SELECT- SWITCH (NCT05814627)
- Testing
- Upadacitinib, Adalimumab
- Where
- 218 sites in United States, Argentina and 23 more
- Volunteers
- 487 people
- Sponsor
- AbbVie
Moderately to Severely Active Rheumatoid Arthritis
Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis
To compare the efficacy between the HLX01 group and the placebo group through the proportion of subjects meeting the ACR20 improvement criteria for remission
- Trial name
- NCT03522415
- Testing
- HLX01, Methotrexate（MTX）
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Shanghai Henlius Biotech
Rheumatoid Arthritis
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately…
- Trial name
- CREDO 4 (NCT03120949)
- Testing
- Olokizumab 64 mg SC q4w, Olokizumab 64 mg SC q2w, Concomitant treatment
- Where
- 239 sites in United States, Argentina and 16 more
- Volunteers
- 2,106 people
- Sponsor
- R-Pharm International, LLC
Rheumatoid Arthritis
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
This randomized, double-blind, parallel group study compares the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of tocilizumab in participants with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT01194414
- Testing
- tocilizumab SC, tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 216 sites in United States, Argentina and 24 more
- Volunteers
- 1,262 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who…
- Trial name
- NCT03813199
- Testing
- ABX464 50mg, ABX464 100mg, Methotrexate
- Where
- 24 sites in Belgium, Czechia and 3 more
- Volunteers
- 60 people
- Sponsor
- Abivax S.A.
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy
This 3 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo in combination with methotrexate (MTX) in patients with moderate to severe active rheumatoid…
- Trial name
- NCT00106522
- Testing
- Methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 168 sites in United States, Australia and 12 more
- Volunteers
- 499 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT05460832
- Testing
- MBS2320 5 mg, MBS2320 20 mg, MBS2320 40 mg
- Where
- 46 sites in Bosnia and Herzegovina, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Modern Biosciences Ltd
Rheumatoid Arthritis (RA)
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
The goal of this study is to evaluate the safety, pharmacokinetic (PK) characteristics, and preliminary efficacy of a new oral chemical drug in : adults aged 18-70 years (male or female) with moderate to severe active rheumatoid…
- Trial name
- NCT07408024
- Testing
- TollB-001
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Toll Biotech Co. Ltd. (Beijing)
Rheumatoid Arthritis
A Retrospective Observational Study on Compliance in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) in Clinical Practice (REMISSION II)
This multicenter, retrospective observational study will evaluate compliance an reasons for withdrawal in patients with moderate to severe active rheumatoid arthritis on treatment with intravenous RoActemra/Actemra (tocilizumab)…
- Trial name
- NCT01649817
- Where
- 24 sites in Greece
- Volunteers
- 183 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
To compare the maintenance of efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with or without other disease modifying antirheumatic drugs therapy with that of methotrexate with or without other…
- Trial name
- NCT01578850
- Testing
- Etanercept
- Where
- 62 sites in Brazil, China and 17 more
- Volunteers
- 491 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
The primary purpose of this study is to identify an appropriate dose of study medication.
- Trial name
- NCT02015520
- Testing
- Clazakizumab
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 143 people
- Sponsor
- CSL Behring
Rheumatoid Arthritis (RA), Anti IL-6R
Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis
A multicenter, randomized, double-blind, placebo-controlled, and active drug-controlled Phase III pivotal clinical trial of recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) for the…
- Trial name
- NCT06726096
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 615 people
- Sponsor
- Beijing VDJBio Co., LTD.
Rheumatoid Arthritis
Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis
This is a multicenter, randomized, double-blind, placebo and tocilizumab controlled phase II trial in RA patients to evaluate the initial efficacy, safety, pharmacokinetic, pharmacodynamic characteristics, and immunogenicity of…
- Trial name
- NCT05957107
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- 15 sites in China
- Volunteers
- 181 people
- Sponsor
- Beijing VDJBio Co., LTD.
Sjogren's Syndrome
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
Primary Objective: To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe systemic disease activity. Secondary Objectives: 1.
- Trial name
- NCT06104124
- Testing
- Dazodalibep
- Where
- 206 sites in United States, Argentina and 24 more
- Volunteers
- 651 people
- Sponsor
- Amgen